J.Y. is a Medical Foundation Research Fellow funded by the Storr Bequest.
Liver Biology and Pathobiology
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo†
Article first published online: 22 DEC 2005
Copyright © 2005 American Association for the Study of Liver Diseases
Volume 43, Issue 1, pages 134–143, January 2006
How to Cite
Yu, J., Qiao, L., Zimmermann, L., Ebert, M. P. A., Zhang, H., Lin, W., Röcken, C., Malfertheiner, P. and Farrell, G. C. (2006), Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 43: 134–143. doi: 10.1002/hep.20994
Potential conflict of interest: Nothing to report.
- Issue published online: 22 DEC 2005
- Article first published online: 22 DEC 2005
- Manuscript Accepted: 5 OCT 2005
- Manuscript Received: 12 JUL 2005
- Cure Cancer Australia Foundation (2005)
- Robert W. Storr Bequest of the Medical Foundation, University of Sydney
- NHMRC Program. Grant Number: 358398
Supplementary material for this article can be found on the H EPATOLOGY website ( http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html )
|jws-hep.20994.tif||575K||The effects of troglitazone on viability of Hep3B and Huh7 cells in culture. HCC cells (1 x 10 6cells) were incubated either alone or in the presence of troglitazone (0.50, 100 &#x03bc;mol/L) for 48 hours and cell viability was measured by the MST method. Treatment with troglitazone caused dose-dependent inhibition of cell viability. *P < .05, **P < .001, troglitazone treated vs. untreated control. Data are mean &#x00b1; SD (n = 3).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.